UAE- Joints pain killer 'Celebrex' is safe: Report


(MENAFN- Khaleej Times) Celebrex is a non-steroidal anti-inflammatory drug (NSAID), specifically a COX-2 inhibitor, which relieves pain and swelling (inflammation is safe and free of any medical warnings, said a top official at the ministry of health and prevention.

He described as incorrect the reports posted in the social media network facilities about the medicine which is manufactured by Pfizer, and that the ministry of health has not received any notification from US Food and Drugs Authority FDA or the European and Australia's medicine authority on the issue, recently.

Stopping the use medicines due to misleading ads causes serious complications in patients and medicine rules in the UAE.

"The wrong ads also diminishes the confidence of the patients and consumers in the entities concerning medicines and the drugs used, hence has adverse effects on the health of the patient and the health of whoever uses these medicines", he regrettably said.

He also appealed to the members of the society to avoid circulating any kind of misleading information received from social media, They should rather report such issues to the ministry of health and designated health authorities.

He said that Pfizer has confirmed that the medicine was approved by most of the countries and health organizations in the world, prominently among which are FDA in 1998, European medicines Agency and GCC is including UAE.

"Celebrex has been used by millions of patients around the world for 17 years and has proven its efficiency and effectiveness in treating arthritis and acute joint pains.


(function(P,o,s,t,Q,r,e){P['PostquareObject']=Q;P[Q]=P[Q]||function(){ (P[Q].q=P[Q].q||[]).push(arguments)},P[Q].l=1*new Date();r=o.createElement(s), e=o.getElementsByTagName(s)[0];r.async=1;r.src=t;e.parentNode.insertBefore(r,e) })(window,document,'script','//widget.engageya.com/_pos_loader.js','__posWidget'); __posWidget('createWidget',{wwei:'POSTQUARE_WIDGET_90498',pubid:166590,webid:131503,wid:90498,on:'postquare'});
Share More > Vote
function ArticleVote_GetCookie(c_name) { if (document.cookie.length>0) { c_start=document.cookie.indexOf(c_name + "="); if (c_start!=-1) { c_start=c_start + c_name.length+1; c_end=document.cookie.indexOf(";",c_start); if (c_end==-1) c_end=document.cookie.length; return unescape(document.cookie.substring(c_start,c_end)); } } return ""; } function ArticleVote() { $.ajax( { type: "POST", url: '/misc/misc/ArticleVote.pbs&guid=608B6210-1ECA-4072-85C5-1497EF8492EA&write=1&d=' + (new Date()).getTime(), success: function(data) { var LData = data || "no response text"; if(LData.indexOf("voted") != -1) { $('#NCS-ArticleVoteLoad').html(LData); ArticleVoteLoad(1); } else alert("You have already voted on this article"); }, error: function(){ console.log('Something went wrong...') } }); } function ArticleVoteLoad(ALoad) { var GVotecookie = ArticleVote_GetCookie('NCSD_ARTICLEVOTE'); var GArticleVoted = 0; GArticleVoted = GVotecookie.replace(/.*?608B6210-1ECA-4072-85C5-1497EF8492EA.*?$/, "1"); if (GArticleVoted == 1) { $('.DivArticleVote').html('VOTED'); $('.DivArticleVote').css("background-color","#db2425"); $('.LiArticleVote').attr('onclick','').unbind('click'); } if(ALoad == 1) $('.SpanArticleVote').load("/misc/misc/ArticleVote.pbs&nocache=1&guid=608B6210-1ECA-4072-85C5-1497EF8492EA"); else $('.SpanArticleVote').load("/misc/misc/ArticleVote.pbs&guid=608B6210-1ECA-4072-85C5-1497EF8492EA"); } ArticleVoteLoad(0);


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Newsletter